MyMD Takes on Inflammatory-Related Diseases with MYMD-1

Published on :

While still in the early stages of development, Baltimore’s MyMD Pharmaceuticals lead therapeutic compound MYMD-1 appears to have the potential to be a pipeline in a pill that can play a role in multiple autoimmune and fibrotic diseases where inflammation plays a key role.

DrugViu to Relocate and Expand Operations in Northern Virginia

Published on :

Launched in New York, two-year-old data science company DrugViu, which has created a comprehensive and diverse Real-World Evidence Platform for immunological research, will relocate its headquarters to Northern Virginia.